An experimental medication slows the progression of the neurodegenerative disease called Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, according to recently released results from a clinical trial.
Departments, Centers, & Programs:
ALS Multidisciplinary Clinic, Healey Center for ALS
15 Parkman Street
Boston, MA 02114-3117
- PhD, Northwestern University
- MD, University of Milan-Medical School
- Residency, Spaulding Rehabilitation Hospital
- Fellowship, Brigham and Women's Hospital
American Board Certifications
- Physical Medicine & Rehabilitation, American Board of Physical Medicine and Rehab
- Neuromuscular Medicine, American Board of Physical Medicine and Rehab
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Press Release
- Aug | 3 | 2020
First Participants Enrolled in the Groundbreaking Trial Led by the Sean M. Healey & AMG Center for ALS at Mass General
As the first ever platform trial for ALS, the HEALEY ALS Platform Trial is testing three proposed drug regimens and will add two more over the next several months.
- Mar | 13 | 2019
The Healey Center for ALS at Mass General Unites the World's Leading Experts to Bring Innovative Trial Approaches to the Field of ALS
Announcing one of the most promising avenues for igniting a paradigm shift in ALS therapy development: the ALS platform trial.
- May | 14 | 2020
Peer-reviewed results of a trial led by the Healey Center’s Dr. Sabrina Paganoni, will be published soon. The CENTAUR trial, highlighted in a Wall Street Journal article, tested a drug that showed promise in slowing muscle decline in individuals with ALS.
- Sep | 3 | 2018
Sabrina Paganoni, MD, PhD, is using technology to find new treatments and improve the care and quality of life for patients with ALS.